Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TS 01

Drug Profile

TS 01

Alternative Names: TS01

Latest Information Update: 22 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beth Israel Deaconess Medical Center; Harvard Medical School
  • Developer Thrombolytic Science International
  • Class Complement C1 inactivator proteins; Neuroprotectants; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Fibrinolytic agents; Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 26 May 2022 Thrombolytic Science in collaboration with Erasmus Medical Center completes a phase II DUMAS trial in Stroke in Netherlands (IV, Infusion) (NCT04256473)
  • 10 Jan 2022 US PTO grants patent protection for TS 01 for treatment of Stroke
  • 29 Oct 2021 Thrombolytic Science has patent protection for TS 01 in USA, Europe, Japan, China, Hong Kong, Mexico and Commonwealth of Independent States
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top